Computationally Selected Multivalent HIV-1 Subtype C Vaccine Protects Against Heterologous SHIV Challenge

Computationally Selected Multivalent HIV-1 Subtype C Vaccine Protects Against Heterologous SHIV Challenge

<b>Background</b>: The RV144 trial in Thailand is the only HIV-1 vaccine efficacy trial to date to demonstrate any efficacy. Genetic signatures suggested that antibodies targeting the variable loop 2 (V2) of the HIV-1 envelope played an important protective role. The ALVAC prime and prot...

Full description

Saved in:
Bibliographic Details
Main Authors: Dieter Mielke, Marina Tuyishime, Natasha S. Kelkar, Yunfei Wang, Robert Parks, Sampa Santra, Wes Rountree, LaTonya D. Williams, Tiffany Peters, Nathan Eisel, Sheetal Sawant, Lu Zhang, Derrick Goodman, Shalini Jha, Adam Zalaquett, Pratamesh Ramasubramanian, Sherry Stanfield-Oakley, Gary Matyas, Zoltan Beck, Mangala Rao, Julie Ake, Thomas N. Denny, David C. Montefiori, Margaret E. Ackerman, Lawrence Corey, Georgia D. Tomaras, Bette T. Korber, Barton F. Haynes, Xiaoying Shen, Guido Ferrari
Format: Article
Language:English
Published: MDPI AG 2025-02-01
Series:Vaccines
Subjects:
HIV-1
subtype C
variable loops 1 and 2
correlate of protection
systems serology
Online Access:https://www.mdpi.com/2076-393X/13/3/231
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:<b>Background</b>: The RV144 trial in Thailand is the only HIV-1 vaccine efficacy trial to date to demonstrate any efficacy. Genetic signatures suggested that antibodies targeting the variable loop 2 (V2) of the HIV-1 envelope played an important protective role. The ALVAC prime and protein boost follow-up trial in southern Africa (HVTN702) failed to show any efficacy. One hypothesis for this is the greater diversity of subtype C viruses in southern Africa relative to CRF01_AE in Thailand. <b>Methods</b>: Here, we determined whether an ALVAC prime with computationally selected gp120 boost immunogens maximizing coverage of diversity of subtype C viruses in the variable V1 and V2 regions (V1V2) improved the protection of non-human primates (NHPs) from a heterologous subtype C SHIV challenge compared to more traditional regimens. <b>Results</b>: An ALVAC prime with Trivalent subtype C gp120 boosts resulted in statistically significant protection from repeated intrarectal SHIV challenges compared to the control. Evaluation of the immunogenicity of each vaccine regimen at the time of challenge demonstrated that different gp120 combination boosts elicited similar high magnitudes of gp120 and breadth of V1V2-binding antibodies, as well as strong Fc-mediated immune responses. Low-to-no neutralization of the challenge virus was detected. A Cox proportional hazard analysis of five pre-selected immune parameters at the time of challenge identified ADCC against the challenge envelope as a correlate of protection. Systems serology analysis revealed that immune responses elicited by the different vaccine regimens were distinct and identified further correlates of resistance to infection. <b>Conclusions</b>: Computationally designed vaccines with maximized subtype C V1V2 coverage mediated protection of NHPs from a heterologous Tier-2 subtype C SHIV challenge.
ISSN:2076-393X

Similar Items